[의약품]Phigenix, Inc./ MUSC Foundation for Research Development 대 Genentech, Inc. 간의 의약품 관련 특허 분쟁
발생일자 2015.03.17
사건번호 3:15-cv-01238
법원국가 UNITED STATES OF AMERICA
관할법원명 D.C.N.D.California(지방법원)
침해권리 특허
원고명 Phigenix, Inc./ MUSC Foundation for Research Development ( 미국 / 외국기업 )
피고명 Genentech, Inc. ( 미국 / 외국기업 )
소송유형 침해금지
분쟁내용
[Phigenix, Inc. et al v. Genentech, Inc.] 사건번호 3:15-cv-01238에 따르면 원고 Phigenix, Inc./ MUSC Foundation for Research Development는 피고 Genentech, Inc.을 상대로 특허 US8080534을 침해하였다는 이유로 미국 캘리포니아 북부 지방법원에 소를 제기하였다.
분쟁결과 분쟁중
산업분류 화학∙바이오 > 의약품
계쟁제품 KADCYLA, ado-trastuzumab emtansine
지재권번호/명칭
US8080534 Targeting PAX2 for the treatment of breast cancer
Targeting PAX2 for the treatment of breast cancer
Abstract
The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the certain embodiments, the method of inhibiting expression of PAX2 is to administrate the subject a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 or by increasing expression of DEFB1 is also provided.
Claims
What is claimed is:
1. A method for treating a breast condition in a subject, comprising administering to a breast tissue of the subject, a composition that (1) inhibits PAX2 expression or PAX2 activity, (2) expresses DEFB1 or (3) inhibits PAX2 expression or PAX2 activity and expresses DEFB1.
2. The method of claim 1, wherein the breast condition is breast cancer or mammary intraepithelial neoplasia (MIN).
3. The method of claim 1, wherein said composition comprises a polynucleotide encoding an siRNA comprising a sequence selected from the group consisting of SEQ ID NOS: 3-6 and 11-15.
4. The method of claim 1, wherein said composition comprises a polynucleotide comprising SEQ ID NO:1 in forward or reverse orientation.
5. The method of claim 4, wherein said polynucleotide comprises the sequence of V-CCTTG-W, wherein V and W are contiguous nucleotide sequences of 1 to 35 nucleotides that flank the PAX2 binding site of DEFB1 promoter, and a complementary sequence thereof.
6. The method of claim 5, wherein said polynucleotide comprises a sequence selected from the group consisting of SEQ ID NOS: 18-21, 25, 26, 28 and 29.
7. The method of claim 1, wherein said composition comprises enalapril.
8. A method of treating breast cancer or MIN in a subject, comprising enhancing expression of DEFB1 in a breast cancer tissue or MIN tissue in the subject.
9. The method of claim 8, wherein the enhancing expression of DEFB1 comprises administering to the breast cancer tissue or MIN tissue in the subject an efficient amount of DEFB1.
10. The method of claim 8, wherein the enhancing expression of DEFB1 comprises administering to the breast cancer tissue or MIN tissue in the subject an efficient amount of an expression vector encoding DEFB1.
11. The method of claim 1, further comprising the step of: administering to the subject an effective amount of an anti-hormonal agent.
12. The method of claim 11, wherein the anti-hormonal agent is Tamoxifen.
13. The method of claim 1, further comprising the step of: administering to the subject an effective amount of an anti-ERBB-2 agent.
14. The method of claim 13, wherein the said anti-ERBB-2 agent is Herceptin.
15. The method of claim 1, further comprising the step of: administering to the subject an effective amount of an anti-Her-2 agent.
16. The method of claim 15, wherein the anti-Her-2 agent is Trastuzumab.
17. The method of claim 1, further comprising the step of: administering to the subject an effective amount of an anti-AIB-1/SRC-3 agent.
18. The method of claim 1, wherein said composition further comprises one or more agents selected from the group consisting of anti-hormanal agents, anti-ERBB-2 agents, anti-Her-2 agents, and anti-AIB-1/SRC-3 agent.
19. A method for treating a breast condition in a subject, comprising: (a) determining the PAX2-to-DEFB1 expression ratio in a diseased breast tissue from said subject; (b) determining the ER/PR status of said diseased breast tissue from said subject; and (c) based on the results of (a) and (b), administering to a breast tissue of said subject, a first composition that (1) inhibits PAX2 expression or PAX2 activity, (2) expresses DEFB1 or (3) inhibits PAX2 expression or PAX2 activity and expresses DEFB1.
20. The method of claim 19, wherein said breast condition is breast cancer or MIN.
21. The method of claim 19, wherein said first composition comprises a polynucleotide encoding an siRNA comprising a sequence selected from the group consisting of SEQ ID NOS: 3-6 and 11-15.
22. The method of claim 19, wherein said first composition comprises a polynucleotide comprising SEQ ID NO:1 in forward or reverse orientation.
23. The method of claim 22, wherein said polynucleotide comprises the sequence of V-CCTTG-W, wherein V and W are contiguous nucleotide sequences of 1 to 35 nucleotides that flank the PAX2 binding site of DEFB1 promoter, and a complementary sequence thereof.
24. The method of claim 23, wherein said polynucleotide comprises a sequence selected from the group consisting of SEQ ID NOS: 18-21, 25, 26, 28 and 29.
25. The method of claim 19, wherein said first composition comprises an antagonist selected from the group consisting of antagonists of angiotensin II, antagonists of angiotensin II receptor, antagonists of angiotensin-converting enzyme (ACE), antagonists of mitogen-activated protein kinase (MEK), antagonists of extracellular signal-regulated kinase 1,2 (ERK1,2), antagonists of signal transducer and activator of transcription 3 (STAT3).
26. The method of claim 19, wherein said first composition comprises a blocker of the RAS signaling pathway.
27. The method of claim 19, wherein said first composition is an anti-PAX2 agent conjugated to an antibody, a receptor or a ligand to target tumor tissue in said subject.
28. The method of claim 19, wherein said first composition is an anti-PAX2 agent comprising a small molecule that interferes or inhibits binding of PAX2 to the DEFB1 promoter.
29. The method of claim 19, wherein the step (c) further comprises administering a second composition comprising an anti-hormonal agent.
30. The method of claim 29, wherein the anti-hormonal agent is Tamoxifen.
31. The method of claim 19, wherein the step (c) further comprises administering a second composition comprising an anti-ERBB-2 agent.
32. The method of claim 31, wherein the anti-ERBB-2 agent is Herceptin.
33. The method of claim 19, wherein the step (c) further comprises administering a second composition comprising an anti-Her-2 agent.
34. The method of claim 33, wherein the anti-Her-2 agent is Trastuzumab.
35. The method of claim 19, wherein the step (c) further comprises administering a second composition comprising an anti-AIB-1/SRC-3 agent.
![[US Patent & Trademark Office, Patent Full Text and Image Database]](http://patft.uspto.gov/netaicon/PTO/patfthdr.gif)
